3 Major Violations Expose Roche Diagnostics Shanghai to Regulatory Penalty
On May 13, 2025, public records from Qichacha revealed that Roche Diagnostics Products (Shanghai) Co., Ltd. has been officially penalized for three serious breaches of China’s occupational health laws.
According to the notice, Roche failed to provide workers with mandatory occupational health training, neglected to arrange health checks for employees in potentially hazardous roles, and withheld crucial information about occupational disease risks during the signing of labor contracts.
The violations are based on the Occupational Disease Prevention Law of the People’s Republic of China, which obligates employers to:
-
Conduct pre-employment and regular health and safety training
-
Offer medical screening for employees exposed to occupational hazards
-
Clearly disclose any potential workplace health risks and protections in the labor contract
Authorities cited Roche’s failure to comply with Article 33, 34, and 35 of the law, emphasizing the employer’s duty to inform and protect employees in environments involving potential exposure to hazardous substances or conditions.
The notice serves as a warning to multinational corporations operating in China that local compliance standards on workplace health and safety remain non-negotiable. As workplace risks come under increasing scrutiny, failure to meet legal obligations can result in both reputational damage and administrative penalties.
Details of the penalty and related documentation were attached in the administrative notice published through official channels. Roche has not yet made a public statement regarding the incident.
Looking for chemical products? Let suppliers reach out to you!
2026-07-13
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
The GLP-1 Sweet Shot in India’s Diabetic Gut
-
Small Pharma Firms Under Threat as Regulator Tightens Quality Norms
-
Merck Nears Acquisition of Cidara to Strengthen Flu Prevention Arsenal
-
Biocon Weighs Merger of Biocon Biologics to Unlock Value
-
After Semaglutide Patent Expiry in India, the Price System Has Been Restructured as More Than 40 Drugmakers Enter the Competition
-
Sun Pharma’s Utreglutide Shows Promising Weight Loss and Liver Fat Reduction
-
Betting on Next-Generation Metabolic Therapies: Pfizer’s Big Wager on Metsera and Its Strategic Reshaping in China
-
India Targets Fake Drug Packaging
Recommend Reading
-
Sun Pharma’s Secret Sauce: Solve the Specific, Win the Market
-
The Oral GLP-1 Cage Match: Orforglipron vs Rybelsus
-
Sun Pharma’s Winning Formula: Precision Over Expansion
-
Wegovy Slips on Price While Mounjaro Defends Its Weight-Loss Crown
-
A New Obesity Pill Enters the Arena With Double-Digit Weight Loss
-
¥20 Million Investment Lands in Qingdao: China and Japan Join Hands to Build High-Active Zinc Oxide Production Base
-
An Explosion Has Occurred in the Jubail Industrial City, Putting 6–8% of Global Petrochemical Production Capacity at Risk
-
Sekisui Specialty Chemicals Has Announced a Global Price Increase
-
August MTBE Market Trends in China
-
In August, the coke market price in China was largely stable with minor fluctuations